Amyloid-β-Derived Peptidomimetics Inhibits Tau Aggregation

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Tau protein aggregation is a key hallmark of Alzheimer's disease (AD), leading to neurodegeneration.
• Peptidomimetics offer a specific strategy to inhibit tau aggregation, distinct from other small molecules.
• Amyloid-beta (Aβ) derived peptides are known to prevent Aβ aggregation.

Purpose of the Study:

• To investigate the efficacy of Aβ-derived peptidomimetics in inhibiting heparin-induced tau aggregation in vitro.
• To evaluate the potential of these peptidomimetics in reversing tau-induced cytotoxicity.

Main Methods:

• In vitro assays using thioflavin S fluorescence, transmission electron microscopy (TEM), and circular dichroism (CD) spectroscopy.
• Analysis of tau aggregation inhibition by KLVFF, P4, P5, and LPFFD peptides.
• Assessment of tau-induced cytotoxicity reversal in a dose-dependent manner.

Main Results:

• The pentapeptide KLVFF demonstrated significant inhibition of tau aggregation.
• Peptides P4 and P5 also inhibited tau assembly, forming short fibrils.
• The beta-sheet breaker peptide LPFFD was ineffective.
• Tested peptides reversed tau-induced cytotoxicity dose-dependently.

Conclusions:

• Amyloid-beta-derived peptidomimetics, particularly KLVFF, P4, and P5, are effective inhibitors of tau aggregation in vitro.
• These peptides show potential for reducing tau-induced neurotoxicity.
• The study suggests these molecules could be valuable therapeutic agents for Alzheimer's disease, targeting both tau and amyloid-beta pathways.